Jubilant Pharma says oral formulation is an affordable, more convenient, easy-to-administer and potentially effective treatment option for COVID-19 patients

The development comes after DCGI (Drugs Controller General of India) gave its nod to foreign-made and approved COVID-19 vaccines following a massive spike in coronavirus cases

India will provide approvals to COVID-19 vaccines approved by health regulators like US FDA within 3 days; detailled guidelines to come soon

Addressing a virtual press briefing on April 13, Dmitriev said its vaccine partnership covers 20 producers in 10 countries including Korea, China and India

Fast-track approval has been given for seven additional sites having production capacity of 10 lakh vials/month. Another 30 lakh vials/month production is lined up.

The company has got permission from the Drug Controller General of India (DCGI) to import the vaccine. Reddy's is also going to tap domestically contract manufactured vaccines as and when companies are allowed to start commercial manufacturing in India

Coronavirus vaccination: After taking the first shot, the vaccine beneficiary will receive a message on his/her registered mobile number about the link to download the vaccination certificate

Drug major Dr Reddy's Laboratories is also going to tap domestically sourced jabs as their production speeds up in India

Indian vaccine manufacturers, including SII, Bharat Biotech, Panacea Biotech, Sanofi's Shanta Biotech, Biological E, Hester Biosciences and Zydus Cadila, have an installed capacity to manufacture 8.2 billion doses of different vaccines per year

India is the leading production hub for Sputnik V. RDIF has signed pacts with Gland Pharma, Hetero Biopharma, Panacea Biotec, Stelis Biopharma, Virchow Biotech to produce over 850 million doses per year

The committee asked the company to submit a comparative analysis of late-stage immunogenicity data from both its Indian studies and an ongoing Russian study.

Shares of HDFC, Maruti Suzuki, SBI Cards, Panacea Biotec, Marico, Adani Ports, HDFC Bank, YES Bank, Bank of India, will be in focus on Tuesday's trade

Production of Sputnik V at Panacea Biotec sites will help facilitate global supply of Sputnik V to international partners of RDIF.

Over 91.15% of patients treated with PegIFN were found to be RT PCR negative by day 7 as compared to 78.90 per cent on the 'standard of care' arm; PegIFN reduced the duration for supplemental oxygen to 56 hours from 84 hours in moderate COVID-19 patients

The Drug Controller General of India (DCGI) has allowed the extension of AstraZeneca coronavirus vaccine's expiration time period from the earlier prescribed six months

India administered 1,87,55,540 first doses of the vaccine in the first 17 days of March. At this rate, it will take 2.36 years for India to vaccinate 70 per cent of its population with the initial dose of the two-dose regime vaccination programme.

AstraZeneca Pharma share gained as much as 1.88 per cent to hit a high of Rs 3,480 after the drug maker received import and market permission from the DCGI for osimertinib tablets (Tagrisso) used in treatment of non-small cell lung cancer

Stock Market News Update Today: Bajaj Auto, Maruti Suzuki, Sun Pharmaceutical Industries, Reliance Industries, UltraTech Cement were among top losers, while Power Grid Corporation, Titan, ONGC and Infosys were among notable gainers.

Shares of Reliance, Infosys, HPCL, IDBI Bank, AstraZeneca, NMDC, V Mart, Happiest Minds Technologies will be in focus in Friday's trading session

Price reduction may unlikely have any impact on final price charged from people vaccinating at private hospitals as Covid-19 vaccines are already subsidised by Centre